SUNNIFORECAST - A phase II study of Nivolumab in combination with Ipilimumab versus Standard of care in advanced or metastatic non-clear cell renal cell carcinoma

Scheich S, Ahrens M, Goekbuget N, Boleti E, Burkholder , Escudier BJ, Goebell P, Gruenwald , Gschwend J, Retz M, Hartmann A, Maroto Rey JP, Miller K, Grimm MO, Siemer S, Panic A, Bergmann L (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Oncology Research and Treatment Karger Publishers

Book Volume: 41

Pages Range: 205-205

Authors with CRIS profile

Peter Goebell Urologische Klinik Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie

Involved external institutions

Klinikum rechts der Isar

Germany (DE) Universitätsklinikum Essen

Germany (DE) Universitätsklinikum Frankfurt am Main (KGU)

Germany (DE) Universitätsklinikum des Saarlandes (UKS)

Germany (DE) Institut Gustave-Roussy

France (FR) Charité - Universitätsmedizin Berlin

Germany (DE) Hospital Universitari Dexeus - Grupo Quirónsalud

Spain (ES) Hochschule für Technik und Wirtschaft des Saarlandes

Germany (DE) Universitätsklinikum Jena

Germany (DE) University College London (UCL)

United Kingdom (GB) Medizinische Hochschule Hannover (MHH) / Hannover Medical School

Germany (DE)

How to cite

APA:

Scheich, S., Ahrens, M., Goekbuget, N., Boleti, E., Burkholder, ., Escudier, B.J.,... Bergmann, L. (2018). SUNNIFORECAST - A phase II study of Nivolumab in combination with Ipilimumab versus Standard of care in advanced or metastatic non-clear cell renal cell carcinoma. (pp. 205-205).

MLA:

Scheich, S., et al. "SUNNIFORECAST - A phase II study of Nivolumab in combination with Ipilimumab versus Standard of care in advanced or metastatic non-clear cell renal cell carcinoma." 2018. 205-205.

BibTeX: Download